A Belatacept Compassionate Use Study for Patients With a Kidney Transplant

Please call 800-398-9157 for information on this study Inclusion Criteria: * Men and women of age 18 years or older inclusive * Recipient of a renal allograft for at least ≥ 2 months * EBV positive * Unable to tolerate a suitable immunosuppression regimen to prevent acute allograft rejection, due to: * Extra-renal toxicity related to CNIs and/or m-TOR inhibitors that is refractory to medical management (eg, uncontrolled seizures) * Contraindication to CNIs and/or m-TOR inhibitors OR * At imminent risk of losing allograft kidney due to nephrotoxicity * Renal failure: ≥ Stage 4 on KDOQI Scale (GFR 15 - 29 cc/min) * And no other renal replacement therapy * Subjects must be receiving the maintenance immunosuppressants MMF, MPA, or AZA Exclusion Criteria: * Any significant infection, extra-renal solid organ (heart, liver, pancreas) or cell (islet, bone marrow, stem cell) transplants, with an unresolved episode of AR within the last 6 weeks * EBV negative